Check Claims Before You Publish

Evidence-based highlights

• Focus areas: Clostridioides difficile epidemiology, recurrence, mortality; antimicrobial surveillance (Global-PPS outpatient module); PPI–CDI interactions; infectious disease epidemiology in low-resource settings — supported by multiple papers across high-quality journals (Clinical Microbiology and Infection; Journal of Antimicrobial Chemotherapy; BMC Infectious Diseases; Journal of Infection; Vaccines) CDI mortality cohort study
• Method & tools contribution: development of an outpatient Global-PPS module (open-access tool for standardized outpatient antimicrobial surveillance) indicates practical method development and translational utility Global-PPS outpatient module
• Collaborative network: many papers are multi-author, multi-institutional, with senior co-authors from Antwerp, Karolinska, Ghent — typical for mid-career researchers building domain expertise and networked outputs (OpenAlex lists University of Antwerp and Karolinska affiliations across works).

Limitations, blind spots, and risks of over-interpretation

1. Citation and output scale: overall metrics (h-index ~6; ~100 citations; ~12–14 works) indicate an early-to-mid career researcher rather than a field-leading authority; quantitative impact is moderate and concentrated in a few papers (OpenAlex metadata shows cited_by_count ~104 and h_index 6) OpenAlex author profile snapshot
2. Study designs: many primary studies are observational (population cohorts, case-series, cross-sectional surveys, and meta-analyses), which can robustly describe associations and burden but are limited for causal inference; several included papers explicitly acknowledge confounding (e.g., ill-health confounding in CDI mortality study) CDI mortality confounding note
3. Geographic/generalizability constraints: several studies are Sweden/Europe-focused or specific-country Global-PPS datasets (e.g., Russia, Sweden, Uganda, Ecuador), so external validity outside those settings requires caution; heterogeneity in healthcare systems can limit generalization.
4. Authorship position variability: Boven appears as first author on method/surveillance work and first/last/middle author on other studies — indicates both lead and collaborative roles but not a consistent single-lab principal-investigator footprint yet.

Concrete strengths

• Topic-focused portfolio on CDI and antimicrobial stewardship — coherent research identity that supports cumulative knowledge-building.
• Publication venues include peer-reviewed specialty journals and accessible open-access outputs — increases reproducibility and dissemination (OpenAlex indicates open-access status for many works).
• Method contribution (Global-PPS outpatient module) demonstrates impact beyond descriptive epidemiology toward tools that change practice/data collection.

What would strengthen the scientific profile most?

1. Lead more large, multi-country prospective cohorts or pooled analyses with clear causal inference strategies (e.g., target trial emulation, instrumental variables) to move from association to stronger causal claims.
2. Produce reproducible data releases and code repositories for major analyses to increase transparency and citations.
3. Develop or co-lead intervention trials (e.g., stewardship interventions, PPI deprescribing trials) to translate observational signals into tested clinical actions.

Representative key papers (selected with short evidence notes)

• CDI mortality cohort (2023) — strong population data showing increased mortality after CDI but acknowledges confounding; supports public-health importance of CDI surveillance CDI mortality cohort
• Antibiotics + PPI interaction (2024) — pooled observational evidence that combined exposure heightens CDI risk; useful signal for stewardship but causal mechanism remains to be proven Antibiotics+PPI CDI risk
• Global-PPS outpatient module (2025) — method/tool paper describing a validated surveillance platform; high translational value for stewardship programs Outpatient Global-PPS tool

Short actionable summary

Annelies Boven is an early–mid career researcher building a focused portfolio on CDI epidemiology and antimicrobial surveillance; current work is evidence-generating (associations, surveillance tools) with moderate citation impact and clear potential for translational contributions if followed by larger prospective or interventional studies.